F Facchinetti
Overview
Explore the profile of F Facchinetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
347
Citations
2212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goyal L, DiToro D, Facchinetti F, Martin E, Peng P, Baiev I, et al.
Ann Oncol
. 2024 Dec;
PMID: 39706336
Background: Fibroblast growth factor receptor (FGFR) inhibitors have significantly improved outcomes for patients with FGFR-altered cholangiocarcinoma, leading to their regulatory approval in multiple countries. As with many targeted therapies, however,...
2.
Barbagallo F, Pedrielli G, Bosoni D, Tiranini L, Cucinella L, Calogero A, et al.
J Endocrinol Invest
. 2023 Feb;
46(8):1623-1632.
PMID: 36735200
Purpose: To study sexual function and distress in women with functional hypothalamic amenorrhea (FHA) compared to women with FHA and an underlying polycystic ovary syndrome (PCOS)-phenotype, considering also their psychometric...
3.
Berchuck J, Facchinetti F, DiToro D, Baiev I, Majeed U, Reyes S, et al.
Ann Oncol
. 2022 Sep;
33(12):1269-1283.
PMID: 36089135
Background: Targeted therapies have transformed clinical management of advanced biliary tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for cancer genomic profiling that overcomes many limitations of...
4.
Menichini D, Spelta E, Rossi E, Monari F, Di Vinci P, Petrella E, et al.
Eur Rev Med Pharmacol Sci
. 2022 Jun;
26(11):3967-3972.
PMID: 35731067
Objective: Obesity is a risk factor for the development of gestational hypertension, with important consequences for both the mother and fetus. This prospective observational study aims to propose an early...
5.
Fratelli N, Prefumo F, Maggi C, Cavalli C, Sciarrone A, Garofalo A, et al.
Ultrasound Obstet Gynecol
. 2022 Mar;
60(3):381-389.
PMID: 35247287
Objective: To evaluate the performance of third-trimester ultrasound for the diagnosis of clinically significant placenta accreta spectrum disorder (PAS) in women with low-lying placenta or placenta previa. Methods: This was...
6.
Chen J, Facchinetti F, Braye F, Yurchenko A, Bigot L, Ponce S, et al.
Ann Oncol
. 2022 Jan;
33(4):434-444.
PMID: 35066105
Background: The development of targeted agents, such as osimertinib for EGFR-mutated non-small-cell lung cancer (NSCLC), has drastically improved patient outcome, but tumor resistance eventually always occurs. In osimertinib-resistant NSCLC, the...
7.
Cortellini A, Ricciuti B, Facchinetti F, Alessi J, Venkatraman D, DallOlio F, et al.
Ann Oncol
. 2021 Aug;
32(11):1391-1399.
PMID: 34400292
Background: Prior antibiotic therapy (pATB) is known to impair efficacy of single-agent immune checkpoint inhibitors (ICIs), potentially through the induction of gut dysbiosis. Whether ATB also affects outcomes to chemo-immunotherapy...
8.
Unfer V, Facchinetti F
Eur Rev Med Pharmacol Sci
. 2021 Jun;
25(11):3936-3937.
PMID: 34156671
No abstract available.
9.
Kiani A, Paolacci S, Calogero A, Cannarella R, Di Renzo G, Gerli S, et al.
Eur Rev Med Pharmacol Sci
. 2021 Mar;
25(5):2390-2402.
PMID: 33755975
Objective: Inositol is a carbocyclic sugar polyalcohol. By epimerization of its hydroxyl groups, nine possible stereoisomers can be generated, two of major physiological and clinical relevance: myo-inositol and D-chiro-inositol. Myo-inositol...
10.
Chiossi G, Facchinetti F, Vergani P, Di Tommaso M, Marozio L, Acaia B, et al.
Ultrasound Obstet Gynecol
. 2020 Aug;
57(2):298-304.
PMID: 32851714
Objective: To assess whether repeat cervical-length (CL) measurement in women discharged from hospital after their first episode of threatened preterm labor can predict their risk of spontaneous preterm birth. Methods:...